Medexus Pharmaceuticals Inc (MDP.TO) has seen a modest uptick over the past week, driven by its recent fiscal performance announcements.
This week, Medexus Pharmaceuticals Inc, a company focused on innovative therapies in the healthcare sector, has experienced a 2.40% increase in its stock price, closing at C$5.06. The recent fiscal results and product performance have captured investor attention, although no new company news has emerged this week to further influence market sentiment.
Investor takeaway: Investors should note Medexus' positive recent performance, driven by strong sales of its leading product, GRAFAPEX. However, the company still faces challenges, including a negative profit margin and overall market volatility.
Advertisement
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeMarket cap
$159.02M
52W high
$5.50
52W low
$2.51
1W change
+2.40%
Beta
1.84
Analyst Price Targets
Based on analyst covering MDP
Wall Street analysts forecast MDP stock price to rise 41.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.25
+41.3% Upside
Current Price
C$5.13
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
30.6%
Annualized
90-Day Vol
39.9%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$6.13
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$5.44 | C$4.90 – C$6.05 |
| 60 trading days | C$5.78 | C$4.98 – C$6.71 |
| 90 trading days | C$6.13 | C$5.11 – C$7.36 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
66.02% YTD Gain
Medexus Pharmaceuticals has seen a remarkable 66.02% increase in its stock price year-to-date, reflecting growing investor confidence in its product pipeline and market strategy.
Bull case
The strong fiscal Q1 2027 results show that GRAFAPEX has had its best performance to date, highlighting the company's growth potential. Analysts are optimistic, suggesting there could be substantial upside for Medexus in the future.
Bear case
Despite the recent positive performance, Medexus has a negative profit margin and return on equity, which raises concerns about its financial health and sustainability in a competitive market.
Recent Price Action
Advertisement
Medexus Pharmaceuticals Inc (MDP.TO) closed at C$5.06, reflecting a 1D decrease of 0.97% but a notable 2.40% increase over the past week. Year-to-date, the stock has surged by 66.02%, indicating strong investor interest and confidence in the company's growth trajectory.
Company News and Catalysts
This week, there were no new announcements from Medexus Pharmaceuticals. However, the company's fiscal Q1 2027 results, released on August 10, 2026, highlighted the strongest quarter of performance for its product GRAFAPEX (treosulfan) to date. This has likely contributed to the recent positive price action as investors react to the sustained growth in sales.
Technical Picture
Currently, Medexus is trading above its 50-day moving average of C$4.92 by 2.8% and significantly above its 200-day MA of C$3.66 by 38.2%. The stock has a beta of 1.84, indicating higher volatility compared to the broader market. The 52-week range is C$2.51 to C$5.50, with the current price sitting at 85% of this range. The latest volume of 34,404 shares is below the 20-day average volume of 54,536 shares, suggesting a potential decrease in trading activity.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
